Article info
PDFClinical science
Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial
- Correspondence to Dominik Fischer, Universitätsklinikum Tübingen Universitäts-Augenklinik, Tubingen, Baden-Württemberg, Germany; dominik.fischer{at}uni-tuebingen.de
Citation
Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial
Publication history
- Received February 19, 2021
- Revised April 26, 2021
- Accepted April 30, 2021
- First published May 18, 2021.
Online issue publication
November 14, 2022
Article Versions
- Previous version (14 November 2022).
- Previous version (14 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.